BioSpace News Archive

Investigators today announced the first patient enrollment in the Blood Purification for the Treatment of Pathogen Associated Shock (PURIFY-RCT) trial.

Thermo Fisher Scientific to Present at Cowen’s 42nd Annual Healthcare Conference.

PharmaEssentia USA Corporation, the U.S. subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) has been updated to include BESREMi®.

Elgan Pharma announced today outstanding results from a Phase III study evaluating the safety and efficacy of ELGN-GI, a proprietary enteral insulin formulation for the treatment of intestinal malabsorption, that causes feeding intolerance in preterm infants.

Soligenix, Inc. announced today that its Senior Vice President and Chief Financial Officer, Jonathan Guarino , has been invited to attend the Q1 Virtual Investor Summit.

Ironwood Pharmaceuticals, Inc., a GI-focused healthcare company, announced that management will be presenting at the following investor conferences:

Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces it has sold its Sculptura™ assets to Empyrean Medical Systems for $15 million in cash.

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that its licensor, The University of Sheffield, has received a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application No. 16/608,611.

Codex DNA, Inc. today announced that it will release its fourth quarter 2021 financial results on Tuesday, March 22, 2022, after the market closes.

Candel Therapeutics, Inc. today announced that Seshu Tyagarajan Ph.D., RAC, has been named as the company’s Chief Technical and Development Officer.